First-Line Osimertinib Beneficial in Advanced NSCLC [News in Brief]

In the FLAURA trial, drug improves survival for a subset of patients with higher incidence of EGFR-mutated disease.

from Cancer via ola Kala on Inoreader http://ift.tt/2kxnDUt
via IFTTT